Edition:
United Kingdom

AcelRx Pharmaceuticals Inc (ACRX.OQ)

ACRX.OQ on NASDAQ Stock Exchange Global Market

4.08USD
18 Oct 2018
Change (% chg)

$-0.10 (-2.39%)
Prev Close
$4.18
Open
$4.14
Day's High
$4.14
Day's Low
$3.95
Volume
104,554
Avg. Vol
296,732
52-wk High
$5.03
52-wk Low
$1.58

Chart for

About

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product... (more)

Overall

Beta: 3.03
Market Cap(Mil.): $231.44
Shares Outstanding(Mil.): 45.38
Dividend: --
Yield (%): --

Financials

  ACRX.OQ Industry Sector
P/E (TTM): -- 85.83 33.69
EPS (TTM): -1.10 -- --
ROI: -63.23 0.58 14.30
ROE: -- 1.62 16.03

AcelRx shares surge after FDA staff says opioid safe

AcelRx Pharmaceuticals Inc's shares surged 30 percent on Wednesday after U.S. Food and Administration staff said the company's opioid treatment was safe and effective, bringing it one step closer to a marketing approval.

10 Oct 2018

UPDATE 2-AcelRx shares surge after FDA staff says opioid safe

Oct 10 AcelRx Pharmaceuticals Inc's shares surged 30 percent on Wednesday after U.S. Food and Administration staff said the company's opioid treatment was safe and effective, bringing it one step closer to a marketing approval.

10 Oct 2018

BRIEF-AcelRx Announces FDA Acceptance Of NDA For Dsuvia

* ACELRX PHARMACEUTICALS INC - DSUVIA PDUFA DATE SET FOR NOVEMBER 3, 2018

24 May 2018

BRIEF-Three Arch's Shares Of AcelRx Stock Acquired In Transaction Led By Leerink Revelation Partners And Industry Ventures

* THREE ARCH'S SHARES OF ACELRX COMMON STOCK ACQUIRED IN A PRIVATE TRANSACTION LED BY LEERINK REVELATION PARTNERS AND INDUSTRY VENTURES

23 May 2018

BRIEF-AcelRx Pharmaceuticals Reports Q1 Loss Per Share $0.23

* ACELRX PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

09 May 2018

BRIEF-Acelrx Resubmits New Drug Application For Dsuvia

* ACELRX PHARMACEUTICALS INC - EXPECTS A SIX-MONTH REVIEW BY FDA WITH A PROJECTED PDUFA DATE IN Q4 2018

09 May 2018

BRIEF-AcelRx Receives Positive CHMP Opinion For Dzuveo For Management Of Acute Moderate To Severe Pain In Medically Monitored Settings

* ACELRX RECEIVES POSITIVE CHMP OPINION FOR DZUVEO™ FOR MANAGEMENT OF ACUTE MODERATE TO SEVERE PAIN IN MEDICALLY MONITORED SETTINGS

27 Apr 2018

Earnings vs. Estimates